Meta-Analysis
Copyright ©The Author(s) 2022.
World J Clin Cases. Jun 26, 2022; 10(18): 6091-6104
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6091
Table 1 Characteristics of selected studies
Ref.
Study design
Patientinclusion criteria
ADA/IFX, n
Definition of remission
Definition of secondary loss of response
Induction of response/remission in wk
Maintenance of response/remission in wk
Adverse events
NOS
Zorzi et al[6], 2012RetrospectiveActive CD49/44CDAI < 150No improvement or worsening 4/654Multiple6
Kestens et al[4], 2013RetrospectiveNaïve CD100/100NSNSNS54Multiple9
Ma et al[17], 2014RetrospectiveNaïve CD101/117NSRequiring dose escalationNSNSNS8
Tursi et al[15], 2014RetrospectiveCD67/59HBI ≤ 5NS6-14NSMultiple8
Cosnes et al[12], 2016ProspectiveNaïve CD264/127CDAI < 150Disease activityNS26Multiple8
Varma et al[8], 2016RetrospectiveNaïve CD18/63CDAI < 150NS1248Multiple7
Narula et al[9], 2016ProspectiveNaïve CD111/251HBI < 5Dose escalation1248Multiple8
Bau et al[14], 2017RetrospectiveRefractory CD62/68NSNSNS168Multiple5
Otake et al[5], 2017 RetrospectiveCD29/39CDAI < 150MultipleNS54NS8
Doecke et al[16], 2017RetrospectiveCD144/183CDAI ≤ 150NS14NSNS7
Benmassaoud et al[7], 2018RetrospectiveNaïve CD77/143HBI ≤ 4Need for dose escalation1248Multiple8
Di Domenicantonio et al[13], 2018RetrospectiveNaïve CD505/367NSNSNSNSMultiple9
Macaluso et al[10], 2019RetrospectiveNaïve and non-naïve CDNaïve: 214/107; non-naïve: 47/47NSNS1248Multiple9
Kaniewska et al[11], 2019RetrospectiveCD95/82CDAI < 150NSNS48Multiple7